Solventum Corporation research snapshot
SOLV AI stock analysis currently reads Solventum Corporation as a healthcare spinoff with durable clinical franchises, improving organic sales, and a still-important balance sheet cleanup story. Q1 2026 sales were $2.007 billion, organic sales grew 2.1%, and management reaffirmed 2026 organic growth and free cash flow guidance. The stock forecast is scenario-based, not a fixed price prediction: upside needs steady organic growth, margin execution, and debt reduction, while downside risk comes from weak free cash flow, separation costs, product or reimbursement pressure, and a failed move below support.
Current price
$79.02
Market cap
$13.87 billion calculated from 175.5 million diluted shares
AI score
66 / 100
Rating
Healthcare spinoff turnaround, watch cash conversion
Trend status
Mixed to constructive: price is near the upper part of the recent setup, but technical feeds still show uneven momentum signals
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Solventum sells medical surgical, dental, health information, and filtration-related healthcare products that sit inside repeat clinical workflows rather than discretionary consumer demand. | Medium-high |
| Moat | The moat comes from installed clinical habits, regulatory approvals, product know-how inherited from 3M, quality systems, global distribution, and switching friction in hospitals and dental practices. | Medium-high |
| Management | CEO Bryan Hanson has deep medtech operating experience from Zimmer Biomet, Medtronic, and Covidien, but the current test is post-spinoff execution and cash discipline rather than resume quality alone. | Medium |
| Financial trend | Q1 2026 reported sales fell 3.0% to $2.007 billion while organic sales grew 2.1%; adjusted EPS rose 10.6% to $1.48, but free cash flow was negative $273 million. | High |
| Valuation | At $79.02 and management 2026 adjusted EPS guidance near $6.40 to $6.60, SOLV trades around 12.2x the guidance midpoint, but the free cash flow yield is low against the roughly $200 million 2026 FCF guide. | Medium-high |
| Technical trend | ChartMill showed price near $79.02 with support near $75.26 and resistance near $80.03, while Investing.com showed weaker RSI and MACD signals, so the setup is constructive but not confirmed. | Medium |
| Risk level | Main risks are spinoff execution, leverage, transition costs, tariff and inflation pressure, reimbursement pressure, product quality issues, weak cash conversion, and organic growth falling below guidance. | Medium-high |
| AI confidence | AI confidence is high for sourced financial facts and medium for forecasts because 2025 net income includes a major divestiture effect and standalone history is short. | High data confidence |
| Investment certainty | SOLV can work if the company converts healthcare brands into steady cash flow, but the stock still needs proof that adjusted earnings are backed by sustainable free cash flow. | Medium |
SOLV AI stock forecast
The SOLV AI stock forecast uses a scenario range built around the $79.02 price reference, management adjusted 2026 EPS guidance midpoint near $6.50, and a three-year earnings multiple framework. The audited model produced a bearish value near $53, a base value near $82, and a bullish value near $110 before any future buybacks, dividends, or acquisitions.
$100 to $112
More likely if organic sales stay at or above 2% to 3%, adjusted operating margin holds near 20%, free cash flow rises above 2026 guidance after transition payments fade, and debt reduction earns a mid-teens earnings multiple.
$76 to $86
More likely if SOLV grows low single digits organically, adjusted EPS stays near the $6.40 to $6.60 guidance range, cash conversion improves gradually, and investors value the company near 12x forward adjusted earnings.
$50 to $58
More likely if free cash flow remains weak, reported sales keep shrinking, transition costs persist, tariffs or reimbursement pressure erode margins, or the market re-rates SOLV toward a high-single-digit earnings multiple.
SOLV AI technical analysis
SOLV AI technical analysis is mixed as of the July 8, 2026 cutoff. ChartMill listed a $79.02 stock price, support near $75.26, resistance near $80.03, and a positive short-term setup, while Investing.com listed RSI near 37.5, MACD near -0.59, a 50-day moving average near $78.19, and a 200-day moving average near $77.53. The practical read is that SOLV is close to resistance and needs follow-through above $80 to confirm the setup.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $79.02 | ChartMill listed this SOLV stock price in its July 2026 profile snapshot. |
| Immediate support | $75.26 | ChartMill cited this support level. A hold above this zone keeps the short-term setup alive. |
| Near resistance | $80.03 | ChartMill cited this resistance level. A close above it would improve the trend-following case. |
| Moving averages | 5-day near $76.15, 50-day near $78.19, 200-day near $77.53 | Investing.com listed these moving averages in its SOLV technical page, with mixed signal labels by lookback period. |
| Momentum | RSI near 37.5, MACD near -0.59 | Investing.com showed weaker momentum even though the price was close to the cited resistance area. |
| Volume | Monitor for expansion above recent average volume | A breakout above $80 is more credible if volume expands alongside improved healthcare equipment peers. |
| Volatility | Medium daily risk | StockInvest cited average daily movements and medium risk in its SOLV technical snapshot. |
| Invalidation | Close below $75 | A close below the support area would weaken the constructive setup and shift attention back to cash-flow and debt risk. |
SOLV AI trading strategy
The SOLV AI trading strategy below is a rules-based research framework, not personal advice. It links the technical setup with Q2 2026 execution, free cash flow conversion, debt reduction, and healthcare equipment peer action.
Watch for SOLV to close above $80.03 and hold that level on follow-through volume. Confirmation should include stable 2026 guidance, adjusted EPS tracking toward the high end of guidance, and no new warning on transition costs.
A failed breakout that falls back below $75 should reduce setup confidence because it would show resistance still controls the chart.
If SOLV pulls back toward $75 without a guidance cut, compare the move with Medtronic, Boston Scientific, Danaher, and diagnostic peers, then check whether free cash flow weakness is seasonal or structural.
Do not treat weakness as a normal pullback if reported sales decline accelerates, margin guidance falls, or debt reduction stalls.
Track Q2 2026 sales, organic growth, adjusted operating margin, adjusted EPS, operating cash flow, free cash flow, net debt, tariff commentary, transition agreement exit payments, and SKU exit effects.
Position sizing should account for spinoff history, leverage, healthcare regulation, product liability, and the gap between adjusted EPS and free cash flow.
Investment research summary
Solventum sells healthcare products and workflow tools that clinicians, hospitals, dental practices, and healthcare administrators use to deliver care, manage information, and improve patient outcomes.
The moat is based on clinical trust, regulatory approvals, installed product habits, manufacturing quality, product breadth, and 3M-origin technical know-how. It is not invincible because hospitals can pressure price and competitors can attack individual categories.
The thesis fails if adjusted EPS is not converted into free cash flow, spinoff costs last longer than expected, healthcare customers delay purchases, product quality problems appear, or debt limits reinvestment flexibility.
Bryan Hanson has relevant medtech leadership experience, and management is focused on a transformation plan. The key evidence to watch is cash generation, portfolio discipline, and whether guidance credibility improves through 2026.
The healthcare equipment and supplies market benefits from aging populations, procedural demand, care efficiency, and healthcare data needs. The offset is regulation, payer pressure, hospital budget discipline, and product liability risk.
At roughly 12.2x the 2026 adjusted EPS guide midpoint, SOLV is not priced like a high-growth medtech leader. The margin of safety depends on whether free cash flow normalizes after transition costs and debt falls from current levels.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price reference | $79.02 | ChartMill SOLV profile | July 8, 2026 |
| Market capitalization verification | $13.87 billion calculated from $79.02 x 175.5 million diluted shares | Pineify financial_rigor.py market-cap check | July 8, 2026 |
| Q1 2026 sales | $2.007 billion, down 3.0% reported and up 2.1% organic | Solventum Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 adjusted EPS | $1.48, up 10.6% year over year | Solventum Q1 2026 earnings release | July 8, 2026 |
| Q1 2026 free cash flow | Negative $273 million | Solventum Q1 2026 earnings release | July 8, 2026 |
| FY2026 guidance | Organic sales growth 2.0% to 3.0%, adjusted EPS $6.40 to $6.60, free cash flow about $200 million | Solventum Q1 2026 earnings release | July 8, 2026 |
| FY2025 revenue | $8.325 billion, cross-checked with Macrotrends and CompaniesMarketCap | Solventum 2025 Form 10-K | July 8, 2026 |
| FY2025 net income | $1.556 billion, with StockTitan rounded to about $1.6 billion | Solventum 2025 Form 10-K | July 8, 2026 |
| Q1 2026 cash and total debt | $561 million cash and equivalents; $5.080 billion total debt | Solventum Q1 2026 Form 10-Q | July 8, 2026 |
| Technical support and resistance | Support $75.26, resistance $80.03 | ChartMill SOLV profile | July 8, 2026 |
| Moving averages and momentum | RSI 37.493, MACD -0.590, 50-day moving average $78.19, 200-day moving average $77.53 | Investing.com SOLV technical analysis | July 8, 2026 |
| Analyst consensus reference | 11 analysts, Buy consensus, $86.27 price target reference | Public.com SOLV forecast page | July 8, 2026 |
This SOLV AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios are based on available public data as of July 8, 2026, and may be wrong if company results, market prices, rates, healthcare policy, or investor sentiment change.
